Home Office

PPL Standard Condition 18 Notification Form

Please use this form to notify the Animals in Science Regulation Unit (ASRU) of procedural-related adverse effects that have exceeded or are likely to exceed the severity limitations or controls described in the project licence. ASRU will use this information to determine whether any further action is required.

Do not use to report:

- adverse effects that are due to non-procedural issues;
- potential non-compliance (report by other means);
- issues without adverse welfare consequences.

If you are in doubt whether or not you need to fill in this form, please contact your assigned Inspector.

Please clearly title your document: **'ASRU_establishment name_PPL number_PPLh surname_date_sc18'** and send to your Inspector (e.g. using cjsm) with the subject heading 'PPL SC 18 Notification PPL [Number] – **Check Home Office's Updated Bridging Ways of Working for updated advice on email addresses and subject headings. Cjsm no longer necessary.**

Establishment Licence name	University of Cambridge
Establishment Licence number	X81BD37B1
Name of PPL holder	Brian Huntly
PPL number	PP3042348 (Huntly) Investigation of normal haematopietic stem cell subversion and the evolution, maintenance and targeting of haematological malignancies
Protocol no	08
Protocol title	Study of the impact of genetic alterations on HSPC function during the development, progression and treatment of blood cancers (Mice)
Severity classification	Moderate

1. Date of incident	14/06/2025
2. Species	Mouse
3. Brief details of study and how the limits or constraints have been breached	The specific study (SP147262) made use of murine cells harbouring a combination of three mutations (*Dnmt3a R882H*, *Npmi1c* & *FLT3-ITD*) that leads to leukaemic transformation with a 100% penetrance. As such, mice under this study plan had received a lethal dose of irradiation (on the 20th of May 2025) followed by intravenous injection of murine cells. The study was comprised of 15 mice. One mouse on study plan was found dead on Saturday 14th of June 2026, 25 days post injection.
4. Have you taken advice from the Named Animal Care and Welfare Officer/Named Veterinary Surgeon/others?	No advice was requested as preliminary results were highly suggestive of leukaemia. The NACWO will be cc'ed on the correspondence of this report.
5. Cause of Problem, if known	Acute leukaemic disease progression. Macroscopic examination of the animal demonstrated splenomegaly, (an obligate phenotype for this model system). This animal had been visually inspected on the previous days (last check on the 13th of June 2025) by the AMB staff and members of our team and displayed no clinical symptoms or weight loss. A peripheral blood sample taken on the 12th of June 2025 did not show elevated white blood counts.

6. Action that has been or will be taken *(For example, formulation of drug changed, supportive treatment given, study design modified). If no action needed, indicate why (for example, none required as study has been terminated and will not be repeated)*	The remaining animals in this cohort were inspected by AMB staff on the morning checks (14th of June 2025) with no animals displaying any clinical signs of ill health. These animals were subsequent culled by a member of the team as by the evening of 14th of June 2025 they were displaying symptoms in line with our experimental endpoints. Their tissues were harvested and preliminary analysis has confirmed leukaemic transformation. With the exception of this single animal that was found dead, all other animals on this study plan displayed clinical symptoms consistent with moderate severity and our expected phenotype and were culled with their tissues harvested and processed. Analysis of the tissues obtained has confirmed leukaemic disease progression.
7. Reported by (name)	George Giotopoulos
8. Date	17/06/2025

**********For official use**********

Inspector's comments and recommendations:

Comments and recommendations	
Inspector name	
Date	